Search Results

You are looking at 21 - 30 of 190 items for :

  • "Renal cell carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Andre P. Fay, Guillermo de Velasco, Thai H. Ho, Eliezer M. Van Allen, Bradley Murray, Laurence Albiges, Sabina Signoretti, A. Ari Hakimi, Melissa L. Stanton, Joaquim Bellmunt, David F. McDermott, Michael B. Atkins, Levi A. Garraway, David J. Kwiatkowski, and Toni K. Choueiri

Recurrent molecular aberrations at the epigenetic, DNA, RNA, and protein levels have been identified in clear cell renal cell carcinoma (ccRCC). 1 Common emerging themes have evolved, including dysregulation of the von Hippel-Lindau ( VHL ) gene

Full access

Updates to the Management of Kidney Cancer

Eric Jonasch

“It is a very exciting time in renal cell carcinoma, with new treatments. Most of which are for clear cell carcinoma,” said Eric Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer

Full access

Small Renal Masses With Tumor Size 0 to 2 cm: A SEER-Based Study and Validation of NCCN Guidelines

Angela Pecoraro, Giuseppe Rosiello, Stefano Luzzago, Marina Deuker, Franciska Stolzenbach, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Alberto Briganti, Anil Kapoor, Cristian Fiori, Francesco Porpiglia, and Pierre I. Karakiewicz

data can provide further detail regarding the distribution of patient and renal cell carcinoma (RCC) characteristics within this special patient group. Based on these considerations, we reexamined patients with RCC with T1a 0- to 2-cm renal tumors to

Full access

CLO19-035: Safety Profile and Adverse Events of Sunitinib as a First-Line Treatment for Advanced/Metastatic Clear-Cell Renal Cell Carcinoma: Pooled Analysis of Randomized Controlled Trials

Tarek Haykal, Babikir Kheiri, Varun Samji, Yazan Zayed, Ragheed Al-Dulaimi, Inderdeep Gakhal, Areeg Bala, Jason Sotzen, Ahmed Abdalla, and Ghassan Bachuwa

Background: Metastatic clear-cell renal cell carcinoma (RCC) is largely incurable, and its treatment remains challenging. Sunitinib, a tyrosine kinase inhibitor, is one of the current standard-of-care options for treatment-naïve patients with

Full access

Predictive Biomarkers for Molecularly Targeted Therapies in Renal Cell Carcinoma

James Brugarolas

A significant challenge in oncology is the identification of predictive biomarkers of therapeutic benefit. The article in this issue by Fay et al (page 820 ) illustrates this issue in renal cell carcinoma (RCC). The challenge encompasses all RCC

Full access

Genetic Kidney Cancer Syndromes

Thai H. Ho and Eric Jonasch

Hereditary renal cell carcinoma (RCC) has been estimated to account for 5% to 8% of all RCC cases, and extrarenal manifestations may present as early as 3 years of age ( Table 1 ). 1 , 2 RCC is a diverse set of cancers that originate from the

Full access

The Right Drug for the Right Patient: Navigating Systemic Therapy Options in Metastatic Renal Cell Carcinoma and Future Directions

Toni K. Choueiri and Robert J. Motzer

Targeted therapies have changed the landscape of metastatic renal cell carcinoma (mRCC), with a current median survival of approximately 30 months reported in contemporary trials, representing a drastic improvement over the 12- to 13-month overall

Full access

CLO24-071: A Propensity Matched Survival Analysis Comparing Partial Versus Radical Nephrectomy in Patients with Metastatic Renal Cell Carcinoma: A National Cancer Database Study

Nathan VanderVeer-Harris, Aden Swayze, Ronscardy Mondesir, Raghuram Reddy, Pushan Prabhakar, Arjun Pon Avudaiappan, Ahmed Eldefrawy, Murugesan Manoharan, and Jorge Caso

Introduction: At the time of diagnosis, renal cell carcinoma can present with metastases in 25%–30% of cases. In carefully selected individuals cytoreductive surgery (partial or radical nephrectomy) can be beneficial. In such cases, radical

Full access

CLO24-068: The Role of Obesity in Influencing Patient Survival in Metastatic Renal Cell Carcinoma Patients Receiving Immunotherapy: A Systematic Review and Meta-Analysis.

Chalothorn Wannaphut, Sakditad Saowapa, Natchaya Polpichai, Pharit Siladech, Manasawee Tanariyakul, Phuuwadith Wattanachayakul, and Pakin Lalitnithi

Background : Body composition can be measured with the help of the body mass index (BMI). When treating individuals with metastatic renal cell carcinoma (mRCC) with immune checkpoint inhibitors (ICIs), it is unclear if having a high BMI is a

Full access

YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial

Chad Tang, Kieko Hara, Alexander D. Sherry, Alejandra G. Serrano, Larisa V. Kostousov, Sharia D. Hernandez, Wei Lu, Li Shen, Amishi Y. Shah, Eric Jonasch, Jose A. Karam, Surena F. Matin, Nizar Tannir, Jing Wang, Pavlos Msaouel, Kanishka Sircar, and Luisa Solis

Introduction: The transition from localized to oligometastatic clear cell renal cell carcinoma (ccRCC) is poorly understood. We hypothesized that tumor immune microenvironment (TIM) dysfunction plays an important role in this transition and has